Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc.

Breye Therapeutics develops novel, orally administered ophthalmology drugs to meet the needs of patients suffering vision loss. The company addresses the unmet medical need for more effective therapies.

Breye Therapeutics

Ophthalmic Consultants of Boston provides eye care services, including cataract surgery, LASIK, and retinal care. The practice is self-described as a multi-specialty ophthalmology practice with a history of innovation since 1969.

Ophthalmic Consultants of Boston

Grin Eye Care provides comprehensive eye care services, including cataract surgery, laser vision correction, and products like glasses and contacts. The company is self-described as dedicated to meeting all ophthalmology needs.

Grin Eye Care

Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases and conditions using its proprietary hydrogel platform technology.

Ocular Therapeutix

OTX at ARVO 2014

ReSure Sealant

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutix’s lead clinical program AXPAXLI™ (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI, is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC, for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.

Sparta Group

Versant Ventures

Ascension Ventures

Polaris Venture Capital

Baxter International

Dan Burgess

SV Health Investors

Polaris Partners

We're pleased to announce that the first subjects in our Phase 3 SOL-1 clinical trial of #AXPAXLI in Wet AMD have been screened. Learn more here: https://ow.ly/WlsM50QAN3R.

#OCUTX #WETAMD

July is UV Safety Month. Don't forget that it's not just your skin that needs protection from the sun - your eyes do too! As you enjoy time outside this summer, remember to wear UV-blocking sunglasses and hats to help prevent damage to your eyes.

#OCUTX #UVSAFETYMONTH

Happy Fourth of July! We hope you have a great day full of fun with family and friends! 

#OCUTX #FourthofJuly

Join the Ocular Therapeutix team!
#NOWHIRING #SALES #OCUTX

Click here to view the full job description:
https://ow.ly/Y2lo50SuQpz

Click here for a full list of open positions:
https://ow.ly/POa450SuQpw

Please join us in welcoming some of our recent new hires! We're so excited to have you on the team! 

#OCUTX #NEWHIRES

Are you attending the Northwestern Ophthalmology and Vision Research Day in Chicago this Friday? If so, don’t forget to visit our booth to Experience DEXTENZA!

Learn more about DEXTENZA at www.dextenza.com. 

#OCUTX #DEXTENZA

Metric
Company Name	Ocular Therapeutix, Inc.	Breye Therapeutics	Ophthalmic Consultants of Boston	Grin Eye Care
Symbol	OCUL
MSH ID	COM:OCUTX	COM:BREYE	COM:EYEBOSTON	COM:GRINEYECARE
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Ophthalmology	Healthcare
Country	US	DK	US	US
Stage
Employee Count	267			11
Website	ocutx.com	breye.com	eyeboston.com	grineyecare.com
LinkedIn	ocular-therapeutix-inc
Founders

Metric
Market Cap	1.11B
Enterprise Value
Monthly Web Traffic		3.26K
Web Traffic Growth		10.82
Valuation
Raised Capital

Metric
Revenue	58.44M
Revenue (LTM)
Revenue (NTM)
Gross Profit	53.16M
EBITDA	-79.40M
Operating Income	-82.38M
Net Income	-80.74M
EPS	-0.94
Diluted EPS	-0.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.91
Operating Profit Margin	-1.41
EBITDA Margin	-1.36
Net Profit Margin	-1.49
Return on Equity	-0.63
Return on Assets	-0.21
Return on Capital Employed	-0.18

COM:OCUTX

Ocular Therapeutix

Last Close

8.52

22/11 21:00

Market Cap

1.11B

Beta: -

Volume Today

819.88K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-5.67
P/B Ratio	50.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	29.00
EV Multiple	-10.81

Metric
Days Sales Outstanding	149.52
Days Payables Outstanding	296.28
Days Inventory Outstanding	174.21
Operating Cycle	347.24
Cash Conversion Cycle	106.71
Asset Turnover	0.23

Metric
Operating Cash Flow	-70.23M
Free Cash Flow	-76.32M
Cash Flow to Debt	-0.85
Operating Cash Flow/Sales	-1.12
Free Cash Flow Yield	-0.13

Metric
Cash & Equivalents	195.96M
Accounts Receivable	-4.85M
Inventory	2.31M
Goodwill
Debt to Capitalization	0.46
Debt to Assets	0.51
Current Ratio	4.03
Quick Ratio	21.29

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.31
R&D to Revenue	1.01
SG&A to Revenue	0.60